OR WAIT null SECS
October 31, 2025
Video
This conference preview with Viet Le, DMSc, PA-C, for the 2025 AHA Scientific Sessions highlights the top 5 trials to watch.
October 23, 2025
Article
GLP-1 RAs may offer benefits beyond adiposity reduction in patients with atherosclerotic cardiovascular disease.
October 20, 2025
Rybelsus marks the first oral GLP-1 for major adverse cardiovascular events in adult patients with T2D, opening a new cardiovascular treatment pathway.
October 11, 2025
A pooled cohort analysis of the phase 3 BROOKLYN and BROADWAY trials spotlighted obicetrapib’s impact on patients at risk of cardiovascular mortality.
October 02, 2025
Amgen announced that evolocumab reduced the risk of MACEs such as heart attack and stroke in patients without any prior history of these events.
September 24, 2025
Investigators have highlighted diabetes and obesity as leading drivers of steadily increasing global cardiovascular mortality rates.
September 23, 2025
Less than optimal outcomes with ASCVD also increased healthcare resource utilization and costs.
Despite prior trials indicating the possibility, the AUSPICE study failed to display any difference in risk between patients receiving the vaccine versus placebo.
Findings from an analysis of GBD 2021 data highlight increases in the absolute number of ASCVD cases and deaths among the working-age population.
September 22, 2025
Although PREVENT was more consistent among the overall population, PCE saw more accurate readings in those taking statins within the trial period.
